Insider Selling: CAMP4 Therapeutics (NASDAQ:CAMP) Director Sells $144,081.00 in Stock

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Director Andrew Schwab sold 32,018 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $4.50, for a total transaction of $144,081.00. Following the completion of the transaction, the director directly owned 2,433,280 shares in the company, valued at $10,949,760. This represents a 1.30% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

CAMP4 Therapeutics Price Performance

CAMP stock traded up $0.02 during trading hours on Friday, reaching $4.48. The stock had a trading volume of 126,663 shares, compared to its average volume of 183,971. CAMP4 Therapeutics Corporation has a fifty-two week low of $1.41 and a fifty-two week high of $7.75. The stock has a 50-day simple moving average of $4.11 and a 200 day simple moving average of $4.33. The stock has a market capitalization of $281.12 million, a PE ratio of -1.93 and a beta of 0.22.

CAMP4 Therapeutics (NASDAQ:CAMP) last announced its quarterly earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. The company had revenue of $1.78 million during the quarter. On average, sell-side analysts forecast that CAMP4 Therapeutics Corporation will post -0.59 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on CAMP shares. JPMorgan Chase & Co. raised shares of CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $5.00 to $9.00 in a research report on Tuesday, June 16th. Weiss Ratings raised CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 14th. Chardan Capital set a $6.50 price target on shares of CAMP4 Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, June 10th. UBS Group set a $15.00 price objective on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. Finally, Piper Sandler restated an “overweight” rating and issued a $15.00 target price (up from $12.00) on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $9.56.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CAMP. Bridgeway Capital Management LLC bought a new position in shares of CAMP4 Therapeutics during the second quarter worth about $36,000. China Universal Asset Management Co. Ltd. acquired a new stake in CAMP4 Therapeutics in the 4th quarter valued at $61,000. Jefferies Financial Group Inc. purchased a new position in CAMP4 Therapeutics in the 4th quarter valued at approximately $70,000. Bank of America Corp DE bought a new position in CAMP4 Therapeutics during the 2nd quarter valued at approximately $78,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in shares of CAMP4 Therapeutics during the fourth quarter valued at approximately $115,000.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.